-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2024-511686-11-00
5
2021-10-05
Multiple Sclerosis in pediatric patients
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus
-
2025-524111-37-00
7
2026-04-28
advanced solid tumors
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-522046-42-00
5
2026-03-24
Colonic disease
-
2025-522674-36-00
5
2026-03-24
Metabolic Dysfunction-Associated Steatotic Liver Disease
-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2024-519393-39-00
4
2026-02-27
Angelman Syndrome
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2025-521802-17-00
5
2026-01-30
Erosive/inflammatory osteoarthritis of the hands
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-523088-39-00
1
2026-01-28
Advanced Solid Tumors
-
2025-522731-34-00
3
2026-01-23
Ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer
-
2024-519820-26-00
4
2026-01-22
Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2024-516471-33-00
4
2026-01-19
Alport Syndrome
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)